ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Ke Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3567-3355; OpenAlex author ID A5101991887. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

A Dual-Action CXCR4-Targeted Peptide-Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.6c00292 ↗
Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine. Co-author DOI 10.1039/d5md00488h ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haiyan Xu · 2 shared papers, 2025–2026 · strength 0.50
- Paper A Dual-Action CXCR4-Targeted Peptide-Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppress… DOI 10.1021/acs.molpharmaceut.6c00292 ↗
- Paper Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses… DOI 10.1039/d5md00488h ↗
Chen Wang · 1 shared paper, 2025 · strength 0.22
- Paper Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses… DOI 10.1039/d5md00488h ↗
Xin Huang · 1 shared paper, 2025 · strength 0.22
- Paper Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses… DOI 10.1039/d5md00488h ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.